SCM
PRLD icon

Soleus Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Soleus Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18M Buy
+3,378,378
New +$14.7M 0.62% 45

Other funds holding PRLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Soleus Capital Management's PRLD Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 3,378,378 shares worth $18M. The stake represents 0.62% of the portfolio and ranks #45 among its holdings.

26 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Soleus Capital Management held 3,378,378 shares of Prelude Therapeutics worth $18M as of Q2 2026.
  • Prelude Therapeutics was a new Soleus Capital Management position in Q2 2026.
  • Prelude Therapeutics made up 0.62% of Soleus Capital Management's portfolio in Q2 2026, its #45 holding.
  • 26 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.